Dermata - DRMA Net earnings per share for the last four quarters

Geopolitical conflicts and sanctions hinder the procurement of biomaterials and the execution of global trials. The current annual EPS TTM growth rate illustrates profit dynamics, where the value of 83.60 characterizes this level. Despite physician confidence in natural rosacea remedies, Dermata Therapeutics (DRMA) consumes capital for R&D, periodically raising funds through secondary equity offerings.
DRMA (Dermata Therapeutics): analytical breakdowns and indicator data

This metric is calculated by comparing the current trailing 12-month earnings per share with the same period last year. This indicator objectively measures the scaling rate of net income, stripped of forecasts. For Dermata Therapeutics (DRMA), this growth depends directly on the commercialization of acne and rosacea treatments. Effective penetration of the therapeutic cosmetics market determines the trajectory of the rolling year net earnings per share. A decline in this figure signals fundamental risks for the stock price.